Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.44
+0.47 (1.66%)
as of Aug 25, 2026, 6:15:49 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Dec 01, 2003
Trading at 15X 2004 earnings. Will have a growth rate of 15/20%. Well diversified number of drugs. Nothing coming off patent until 2007. The whole area has been hit hired on the concerns of US pricing of drugs, but feels the bill will be positive.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$34.17

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2003
(A top pick July 10/03. No change.) There is something wrong with the drug stocks. They are all trading poorly and he thinks they want to go lower.
Photo of Ross HealyRoss HealyUnlock Rating
$33.57

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 19, 2003
Will have 100 different drugs in the next 3 or 4 years. Have enormous cash flow. Paying down their debt. Debt/equity ratio is quite strong. Weak US$ will be of benefit as they are international. 2% dividend.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.18

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2003
Pharmaceutical sector has been very frustrating. OK buy for a long-term investment. Could still be some downside. Expecting to file 22 to 25 new drugs between now and 2006. Generates tremendous cash flow. Earnings visibility is good.
Photo of Stephane RochonStephane RochonUnlock Rating
$30.97

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 15, 2003
(A top pick Sep 19/03. Down 1.8%.) Still likes the area and this is the premier company.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$30.60

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 03, 2003
Drug industry has been experiencing difficulties over the past 12 months. Thinks the industry has growth going forward.
Photo of Ray SteeleRay SteeleUnlock Rating
$30.78

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 29, 2003
Viagra is about to have its first major competitor, which could be a significant threat. Pharmaceutical industry suffers from trademark litigations.
Photo of David BaskinDavid BaskinUnlock Rating
$30.89

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 26, 2003
One of the best pharmaceutical companies but have concerns about pharmaceutical companies because of a lot of pressure on prices. The pipeline, two to three years out looks pretty thin.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$30.56

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Sep 25, 2003
Has a strong pipeline and strong products. They've taken some write-offs of Pharmacia from their balance sheet. Model price is $36/37.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$30.53

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 23, 2003
Investors are worried about generic drugs coming in. Likes the sector and likes the valuation.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$31.60

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 19, 2003
The big pharmas are trading at low multiples. Trading at 15 X 2004 earnings. Great value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$31.45

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2003
One of the premier drug companies in the world. Good dividend. Generates a lot of cash. Have 20 new drugs that they'll be releasing. Good price.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$32.05

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 04, 2003
This stock and Merk are not acting well. Some talk of downward earning revisions. Seeing pressures on high drug prices.
Photo of Ross HealyRoss HealyUnlock Rating
$30.60

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Sep 03, 2003
Has a big portfolio of drugs. Buying under $30. Trading at a significant discount to the market. Profit margins are shrinking because of government pressures because of deficits. Competition from generic drugs.
Photo of Brad WillockBrad Willock
Owned
Unlock Rating
$30.88

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 29, 2003
In a decline in the charts.
Photo of David ChapmanDavid Chapman
No
Unlock Rating
$29.92

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 751 to 765 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like